Atogepant reduces triptan use: a pharmacoeconomic analysis in migraine prevention
Abstract Background Migraine is a leading cause of disability worldwide, impairing quality of life and productivity. Preventive therapies aim to reduce attack frequency, severity and the need for acute medications. Oral atogepant (60 mg), a calcitonin gene-related peptide (CGRP) receptor antagonist,...
Gorde:
| Egile Nagusiak: | , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2026-06-01
|
| Saila: | The Journal of Headache and Pain |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s10194-026-02434-8 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|